Application Value of Cinacalcet and Calcitriol in Patients with Chronic Kidney Diseases-mineral and Bone Disorder
Objective:To investigate the application value of Cinacalcet and Calcitriol in patients with chronic kidney diseases-mineral and bone disorder(CKD-MBD).Method:A total of 94 patients with CKD-MBD admitted to Liupanshui People's Hospital from December 2018 to November 2023 were selected and divided into two groups by random number table method,with 47 cases in each group.The control group was treated with hemodialysis(HD)combined with hemoperfusion(HP),and the observation group was treated with Cinacalcet and Calcitriol on the basis of the control group.Blood calcium,blood phosphorus,intact parathyroid hormone(iPTH),ejection fraction(EF),bone alkaline phosphatase(BALP),osteoprotegerin(OPG),left ventricular myocardial mass index(LVMI),coronary artery calcification(CAC)and adverse events were compared between the two groups.Result:After treatment,the levels of blood calcium,EF and OPG in the observation group were higher than those in the control group,while the levels of blood phosphorus,iPTH,BALP and CAC score in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion:On the basis of conventional treatment,the addition of Cinacalcet and Calcitriol can improve the metabolic abnormalities of CKD-MBD patients,promote the recovery of blood calcium,blood phosphorus,iPTH and related indexes of bone metabolism,and also have certain advantages in inhibiting coronary artery calcification and promoting the improvement of cardiac function.
Chronic kidney diseases-mineral and bone disorderCinacalcetCalcitriolMetabolic indexesCardiovascular risk
万方数据
维普
